Afamelanotide

Afamelanotide is a synthetic tridecapeptide analog of alpha-melanocyte-stimulating hormone (alpha-MSH) designed for enhanced potency and metabolic stability. The compound received FDA approval for erythropoietic protoporphyria (EPP), a rare genetic disorder causing extreme photosensitivity, making it the first approved therapy for this condition.

The key structural modifications include replacement of methionine at position 4 with norleucine (eliminating a common oxidation site) and substitution of L-phenylalanine at position 7 with D-phenylalanine (enhancing receptor binding and resistance to enzymatic degradation). These changes increase potency and duration of action compared to native alpha-MSH.

Afamelanotide works primarily through MC1R activation in melanocytes, stimulating eumelanin synthesis and providing photoprotection. Eumelanin absorbs UV radiation and neutralizes free radicals, protecting skin cells from photodamage. For EPP patients whose porphyrin accumulation makes them extremely light-sensitive, this enhanced melanization enables significantly improved light tolerance.

Beyond its approved indication, afamelanotide has research applications in understanding melanogenesis, studying MC1R-mediated signaling, and investigating photoprotection strategies. Its demonstrated clinical safety profile also informs development of other melanocortin-based therapeutics.